K
58.66
-2.34 (-3.84%)
| 前收盘价格 | 61.00 |
| 收盘价格 | 60.29 |
| 成交量 | 587,520 |
| 平均成交量 (3个月) | 760,226 |
| 市值 | 4,220,529,664 |
| 价格/销量 (P/S) | 99.25 |
| 股市价格/股市净资产 (P/B) | 4.12 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业利益率 (TTM) | -336.77% |
| 稀释每股收益 (EPS TTM) | -3.11 |
| 季度收入增长率 (YOY) | 114.80% |
| 总债务/股东权益 (D/E MRQ) | 10.98% |
| 流动比率 (MRQ) | 8.49 |
| 营业现金流 (OCF TTM) | -234.06 M |
| 杠杆自由现金流 (LFCF TTM) | -136.32 M |
| 资产报酬率 (ROA TTM) | -19.47% |
| 股东权益报酬率 (ROE TTM) | -32.17% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Kymera Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.1
| 分析师共识 | 4.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.10 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 2.50% |
| 机构持股比例 | 104.98% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2025 | 4,896,462 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 90.00 (Guggenheim, 53.43%) | 购买 |
| 中 | 72.50 (23.59%) | |
| 低 | 63.00 (Oppenheimer, 7.40%) | 购买 |
| 平均值 | 75.00 (27.86%) | |
| 总计 | 10 购买 | |
| 平均价格@调整类型 | 57.34 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 05 Nov 2025 | 70.00 (19.33%) | 购买 | 59.89 |
| 17 Sep 2025 | 60.00 (2.28%) | 购买 | 48.12 | |
| HC Wainwright & Co. | 05 Nov 2025 | 84.00 (43.20%) | 购买 | 59.89 |
| 18 Sep 2025 | 70.00 (19.33%) | 购买 | 51.16 | |
| Wells Fargo | 05 Nov 2025 | 69.00 (17.63%) | 购买 | 59.89 |
| Guggenheim | 03 Nov 2025 | 90.00 (53.43%) | 购买 | 59.72 |
| BTIG | 22 Oct 2025 | 75.00 (27.86%) | 购买 | 55.80 |
| Mizuho | 21 Oct 2025 | 81.00 (38.08%) | 购买 | 58.32 |
| Citigroup | 17 Oct 2025 | 80.00 (36.38%) | 购买 | 59.83 |
| Oppenheimer | 01 Oct 2025 | 63.00 (7.40%) | 购买 | 54.66 |
| Truist Securities | 30 Sep 2025 | 68.00 (15.92%) | 购买 | 56.60 |
| RBC Capital | 16 Sep 2025 | 70.00 (19.33%) | 购买 | 48.78 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MAINOLFI NELLO | - | 60.03 | -30,000 | -1,800,900 |
| 累积净数量 | -30,000 | |||
| 累积净值 ($) | -1,800,900 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 60.03 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MAINOLFI NELLO | 职员 | 29 Oct 2025 | 自动卖出 (-) | 30,000 | 60.03 | 1,800,900 |
| MAINOLFI NELLO | 职员 | 29 Oct 2025 | 执行期权 | 30,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合